Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1Dermatologic 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1GATA2 Deficiency 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5Whole-Body Irradiation 5Mycophenolic Acid 4Tacrolimus 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Cyclosporine 3Busulfan 3fludarabine 2apixaban 2Methotrexate 2Melphalan 2Lenalidomide 2Etoposide 2CT-P10 2Biopsy 2Azacitidine 2venetoclax 1thymoglobulin 1merphos 1ivosidenib 1ibrutinib 1edoxaban 1Vorinostat 1Vancomycin 1Thiotepa 1Teicoplanin 1TAK-243 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vorinostat × Classical hematology × 30 days × Clear all
NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡